0

Close
 
Upcoming Allied Market Research
2023
Methadone Market

Methadone Market

by Mode of Administration (Oral Medicine, Injections) and by Application (Operation, Detoxification, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A03267
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Methadone Market

Request Now !

Methadone is an opioid medication utilized for the treatment of pain and as maintenance therapy. The medication helps to reduce cravings and withdrawal symptoms in people with opioid addiction. In addition, it helps to block the high sensation in parts of the brain and spinal cord that are caused by using opiates. Methadone helps to manage additions in patient dependent to heroin, morphine, or prescription painkillers. It can be used for a short or long duration depending on the requirement of the patient.

Rise in the number of people addicted to various opioid such as heroin and morphine is a major driving factor of the market. Moreover, increase in awareness towards the use of this medication and rise in number of people seeking help to detox boost the market growth. In addition, as the medication can be used for pain management, rise in the number of people with chronic pain is expected to increase the demand for methadone. However, the side effects associated with the use of methadone restrain the market growth.

The global methadone market is segmented based on mode of administration, application, and geography. Based on mode of administration, the market is classified into oral medicine and injections. Oral medicine is further bifurcated into tablets and liquid. Based on application, the market is categorized into operation, detoxification, and other. Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Qinghai Pharm, Roxane (Boehringer Ingelheim), CentralPharm, Mallinckrodt, Macfarlan Smith, VistaPharm, Diskets, Methadoes, Aurolife Pharma LLC, and Dolophine are provided in this report.

Key Benefits

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global market.
  • This report entails the detailed quantitative analysis of the current market and estimations which assists to identify the prevailing market opportunities.
  • The projections in this report are made by analyzing the current trends and future market potential in terms of value.
  • Competitive intelligence (of leading manufacturers and distributors of disposable gloves) helps understand the competitive scenario across the geographies
  • An in-depth analysis of current research and clinical developments within market is provided with key market dynamic factors that helps understand the behavior of the market

 Methadone Market Report Highlights

Aspects Details
By Mode of Administration
  • Oral Medicine
    • Tablets
    • Liquid
  • Injections
By Application
  • Operation
  • Detoxification
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Diskets, Dolophine, Aurolife Pharma LLC, Roxane (Boehringer Ingelheim), Methadoes, Mallinckrodt, Qinghai Pharm, VistaPharm, Macfarlan Smith, CentralPharm
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: METHADONE MARKET, BY MODE OF ADMINISTRATION

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Mode Of Administration

    • 4.2. Oral Medicine

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Tablets

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Liquid

        • 4.2.4.1. Market Size and Forecast

    • 4.3. Injections

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: METHADONE MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Operation

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Detoxification

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: METHADONE MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Mode Of Administration

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Methadone Market

        • 6.2.5.1. Market Size and Forecast, By Mode Of Administration
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Methadone Market

        • 6.2.6.1. Market Size and Forecast, By Mode Of Administration
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Methadone Market

        • 6.2.7.1. Market Size and Forecast, By Mode Of Administration
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Mode Of Administration

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Methadone Market

        • 6.3.5.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Methadone Market

        • 6.3.6.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Methadone Market

        • 6.3.7.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Methadone Market

        • 6.3.8.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Methadone Market

        • 6.3.9.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Methadone Market

        • 6.3.10.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Methadone Market

        • 6.3.11.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Mode Of Administration

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Methadone Market

        • 6.4.5.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Methadone Market

        • 6.4.6.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Methadone Market

        • 6.4.7.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Methadone Market

        • 6.4.8.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Methadone Market

        • 6.4.9.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Methadone Market

        • 6.4.10.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Methadone Market

        • 6.4.11.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Methadone Market

        • 6.4.12.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Methadone Market

        • 6.4.13.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Mode Of Administration

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Methadone Market

        • 6.5.5.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Methadone Market

        • 6.5.6.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Methadone Market

        • 6.5.7.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Methadone Market

        • 6.5.8.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Methadone Market

        • 6.5.9.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Methadone Market

        • 6.5.10.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Qinghai Pharm

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Roxane (Boehringer Ingelheim)

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. CentralPharm

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Mallinckrodt

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Macfarlan Smith

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. VistaPharm

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Diskets

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Methadoes

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Aurolife Pharma LLC

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Dolophine

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL METHADONE MARKET, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL METHADONE MARKET FOR ORAL MEDICINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL METHADONE MARKET FOR INJECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL METHADONE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL METHADONE MARKET FOR OPERATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL METHADONE MARKET FOR DETOXIFICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL METHADONE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL METHADONE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. NORTH AMERICA METHADONE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 12. U.S. METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 13. U.S. METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 14. CANADA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 15. CANADA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. MEXICO METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 18. EUROPE METHADONE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 21. FRANCE METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 22. FRANCE METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. ITALY METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 26. ITALY METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. SPAIN METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 28. SPAIN METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. UK METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 30. UK METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. RUSSIA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 32. RUSSIA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC METHADONE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. CHINA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 39. CHINA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. JAPAN METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. INDIA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 43. INDIA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. SOUTH KOREA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. AUSTRALIA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 47. AUSTRALIA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. THAILAND METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 49. THAILAND METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. MALAYSIA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 51. MALAYSIA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. INDONESIA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 53. INDONESIA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. LAMEA METHADONE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. BRAZIL METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 60. BRAZIL METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. SOUTH AFRICA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 62. SOUTH AFRICA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. SAUDI ARABIA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. SAUDI ARABIA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 65. UAE METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 66. UAE METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. ARGENTINA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. ARGENTINA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. REST OF LAMEA METHADONE, BY MODE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF LAMEA METHADONE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. QINGHAI PHARM: KEY EXECUTIVES
  • TABLE 72. QINGHAI PHARM: COMPANY SNAPSHOT
  • TABLE 73. QINGHAI PHARM: OPERATING SEGMENTS
  • TABLE 74. QINGHAI PHARM: PRODUCT PORTFOLIO
  • TABLE 75. QINGHAI PHARM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 76. ROXANE (BOEHRINGER INGELHEIM): KEY EXECUTIVES
  • TABLE 77. ROXANE (BOEHRINGER INGELHEIM): COMPANY SNAPSHOT
  • TABLE 78. ROXANE (BOEHRINGER INGELHEIM): OPERATING SEGMENTS
  • TABLE 79. ROXANE (BOEHRINGER INGELHEIM): PRODUCT PORTFOLIO
  • TABLE 80. ROXANE (BOEHRINGER INGELHEIM): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. CENTRALPHARM: KEY EXECUTIVES
  • TABLE 82. CENTRALPHARM: COMPANY SNAPSHOT
  • TABLE 83. CENTRALPHARM: OPERATING SEGMENTS
  • TABLE 84. CENTRALPHARM: PRODUCT PORTFOLIO
  • TABLE 85. CENTRALPHARM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. MALLINCKRODT: KEY EXECUTIVES
  • TABLE 87. MALLINCKRODT: COMPANY SNAPSHOT
  • TABLE 88. MALLINCKRODT: OPERATING SEGMENTS
  • TABLE 89. MALLINCKRODT: PRODUCT PORTFOLIO
  • TABLE 90. MALLINCKRODT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. MACFARLAN SMITH: KEY EXECUTIVES
  • TABLE 92. MACFARLAN SMITH: COMPANY SNAPSHOT
  • TABLE 93. MACFARLAN SMITH: OPERATING SEGMENTS
  • TABLE 94. MACFARLAN SMITH: PRODUCT PORTFOLIO
  • TABLE 95. MACFARLAN SMITH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. VISTAPHARM: KEY EXECUTIVES
  • TABLE 97. VISTAPHARM: COMPANY SNAPSHOT
  • TABLE 98. VISTAPHARM: OPERATING SEGMENTS
  • TABLE 99. VISTAPHARM: PRODUCT PORTFOLIO
  • TABLE 100. VISTAPHARM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. DISKETS: KEY EXECUTIVES
  • TABLE 102. DISKETS: COMPANY SNAPSHOT
  • TABLE 103. DISKETS: OPERATING SEGMENTS
  • TABLE 104. DISKETS: PRODUCT PORTFOLIO
  • TABLE 105. DISKETS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. METHADOES: KEY EXECUTIVES
  • TABLE 107. METHADOES: COMPANY SNAPSHOT
  • TABLE 108. METHADOES: OPERATING SEGMENTS
  • TABLE 109. METHADOES: PRODUCT PORTFOLIO
  • TABLE 110. METHADOES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. AUROLIFE PHARMA LLC: KEY EXECUTIVES
  • TABLE 112. AUROLIFE PHARMA LLC: COMPANY SNAPSHOT
  • TABLE 113. AUROLIFE PHARMA LLC: OPERATING SEGMENTS
  • TABLE 114. AUROLIFE PHARMA LLC: PRODUCT PORTFOLIO
  • TABLE 115. AUROLIFE PHARMA LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. DOLOPHINE: KEY EXECUTIVES
  • TABLE 117. DOLOPHINE: COMPANY SNAPSHOT
  • TABLE 118. DOLOPHINE: OPERATING SEGMENTS
  • TABLE 119. DOLOPHINE: PRODUCT PORTFOLIO
  • TABLE 120. DOLOPHINE: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL METHADONE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL METHADONE MARKET
  • FIGURE 3. SEGMENTATION METHADONE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN METHADONE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALMETHADONE MARKET
  • FIGURE 11. METHADONE MARKET SEGMENTATION, BY BY MODE OF ADMINISTRATION
  • FIGURE 12. METHADONE MARKET FOR ORAL MEDICINE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. METHADONE MARKET FOR INJECTIONS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. METHADONE MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. METHADONE MARKET FOR OPERATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. METHADONE MARKET FOR DETOXIFICATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. METHADONE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 19. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 20. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 21. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 22. COMPETITIVE DASHBOARD
  • FIGURE 23. COMPETITIVE HEATMAP: METHADONE MARKET
  • FIGURE 24. Top player positioning, 2022
  • FIGURE 25. QINGHAI PHARM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 26. QINGHAI PHARM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 27. QINGHAI PHARM: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 28. ROXANE (BOEHRINGER INGELHEIM): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 29. ROXANE (BOEHRINGER INGELHEIM): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 30. ROXANE (BOEHRINGER INGELHEIM): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 31. CENTRALPHARM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. CENTRALPHARM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. CENTRALPHARM: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. MALLINCKRODT: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. MALLINCKRODT: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. MALLINCKRODT: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. MACFARLAN SMITH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. MACFARLAN SMITH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. MACFARLAN SMITH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. VISTAPHARM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. VISTAPHARM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. VISTAPHARM: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. DISKETS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. DISKETS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. DISKETS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. METHADOES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. METHADOES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. METHADOES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. AUROLIFE PHARMA LLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. AUROLIFE PHARMA LLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. AUROLIFE PHARMA LLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. DOLOPHINE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. DOLOPHINE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. DOLOPHINE: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Methadone Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers